Data investigation
Losing Weight Predicted More Heart Attacks
A prespecified analysis of 17,604 people found semaglutide's cardiovascular protection largely independent of weight lost. In the placebo arm, losing weight predicted more cardiac events.
A prespecified analysis of 17,604 people in the SELECT trial asked whether semaglutide’s protection against heart attacks came from the weight it removed. The answer was mostly no.[1] And in the placebo group, the same analysis found that losing weight was associated with more cardiovascular events. That second finding is the more instructive of the two.
The benefit did not follow the weight
Everyone in SELECT was at least 45, carried a BMI of 27 or more, and had heart disease already diagnosed; none had diabetes. Across 41 countries, half drew weekly semaglutide at 2.4 mg and half a placebo. This analysis looked inside that result to ask what the protection tracked.
- Benefit appeared across every baseline category of body weight and waist circumference. Heavier and lighter participants gained similarly.
- Weight lost by week 20 showed no linear relationship to heart attacks and strokes afterward.
- Waist reduction did track it, both at week 20 and over 104 weeks.
- An estimated 33% of the benefit was mediated through waist reduction (hazard ratio 0.86, 95% CI 0.77–0.97 after adjusting for changes over time).
The authors’ own interpretation is that the cardioprotective effect was independent of baseline adiposity and of weight loss, with only a small association with waist circumference. That points to mechanisms beyond fat reduction. A model that projected a 22% cut in heart risk for people who have never had heart disease rests on the opposite assumption, routing the whole benefit through five risk factors.
Two-thirds of the heart benefit is not explained by anything the scale or the tape measure recorded.
That waist matters while weight does not is itself informative. Waist circumference tracks visceral fat (the metabolically active fat around the organs), while body weight lumps that together with muscle, bone and water. Two people losing the same weight can lose very different tissue, which is a recurring theme in this drug class.
We reached a similar conclusion from a much weaker analysis, a post-hoc mediation study in sleep apnea, in is it just the weight loss. SELECT answers the same question with a prespecified analysis, in 17,604 people, against a hard endpoint.
The sentence in the placebo column
The likeliest explanation is a familiar one. When no drug is causing it, weight loss is often a sign of illness: developing cancer, heart failure, or the general decline that can precede a cardiac event. In that case weight falls because something is wrong. The weight loss is a symptom, and the cardiac event follows for the same underlying reason.
Epidemiologists call this reverse causation, and it is why decades of observational studies linking weight loss to worse outcomes were so hard to interpret. This instance stands out because of where it appeared: inside a randomized controlled trial, in the control arm, where it cannot be waved away as a defect of observational data.
The lesson applies beyond this trial. Any study that reports weight change as an outcome or a predictor, without establishing what caused it, is reporting an ambiguous quantity. Diet research leans on that quantity more than most, which makes a Mediterranean diet trial that counted heart attacks instead unusual.
What it means practically
- The cardiovascular benefit is not a reward for losing weight. In SELECT, people who lost less were protected about as much as people who lost more.
- That is reassuring for slow responders, who often conclude the drug is not working.
- Waist may be the better thing to watch than weight, and it is the cheaper measurement.
- Unexplained weight loss without a drug is a reason to see a doctor, not a success.
Two limits belong with all of it. The trial was funded by Novo Nordisk, which makes semaglutide; that is ordinary, and Cochrane’s semaglutide review found most of the drug’s trials were paid for by its manufacturer. And the 33% mediation figure is a modeling estimate that rests on assumptions trial data cannot verify, the same caution that applies to every mediation analysis.
Frequently Asked Questions
References
- 1.Deanfield J, Lincoff AM, Kahn SE, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial The Lancet. 2025. PMID: 41138739.
Compare the sellers
Related research
A Biomarker Is Not an Outcome
Sixteen cardiovascular risk markers were measured in SURMOUNT-1 at 72 weeks, and most improved substantially. Cardiology has learned twice, expensively, why that is not the same as preventing events.
8 min read
Is It Just the Weight Loss?
Every benefit reported for these drugs runs into the same question. A post hoc analysis of the SURMOUNT-OSA trials tried to separate the drug from the weight, and found the sleep apnea improvement doing work of its own.
7 min read
The Thing That Makes Regain Inevitable
Metabolic adaptation is the leading explanation for why weight loss plateaus and returns. A study asked whether tirzepatide interrupts it. In mice it did; in people it did not.
7 min read
Genetics Caused It, and the Drug Still Worked
MC4R mutations are the most common single genetic cause of obesity, and sit at the center of the brain's appetite pathway. Carriers in SURMOUNT-1 lost 18.3% of their weight against 19.9% in everyone else.
6 min read
Where the Evidence Is Strongest
Most of what this register examines has something wrong with it. This does not: a synthesis of 13 trials rates the cardiovascular and kidney benefits in chronic kidney disease at high certainty.
7 min read
The One Place People Felt Better
No obesity drug improved general quality of life across 43 trials. Both heart failure trials produced large symptom improvements. Those findings are not in conflict, because the heart failure trials used a disease-specific symptom measure.
8 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
YourEra
Semaglutide at $99/month, well below the typical price
From $99/mo
Get started →Eden
Coverage in all 50 states, which most sellers will not confirm
From $99/mo
Get started →Found
People who want clinician visits billed to commercial insurance, with compounded medication in the plan price
From $149/mo + membership
Get started →